CriticalReversible MAO-A inhibitor (RIMA)×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase, mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Paroxetine blocks serotonin reuptake, and together with a monoamine oxidase inhibitor (MAOI) it can cause serotonin syndrome. The paroxetine SmPC therefore contraindicates the combination and names moclobemide among the reversible MAOIs (paroxetine SmPC, AEMPS). The paroxetine label of the US Food and Drug Administration (FDA) contraindicates paroxetine with MAOIs and within 14 days of stopping them. Paroxetine inhibits the enzyme CYP2D6, which takes part in moclobemide metabolism. According to the moclobemide SmPC, such changes are generally not therapeutically important and should not need a dose change, because moclobemide has other metabolic pathways (moclobemide SmPC, AEMPS).
Symptoms
Serotonin syndrome causes mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, fever), neuromuscular signs (tremor, rigidity, muscle jerks, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (paroxetine label, US Food and Drug Administration, FDA). Isolated severe cases with high fever, confusion, hyperreflexia and muscle jerks (myoclonus) have occurred in people taking moclobemide with serotonin-raising antidepressants, paroxetine included (moclobemide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Extreme agitation can progress to delirium and coma. Blood pressure, pulse and temperature can swing quickly, and the condition can be life-threatening (paroxetine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish paroxetine summary of product characteristics (SmPC) lists moclobemide among the monoamine oxidase inhibitors (MAOIs) that must not be taken with paroxetine (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The paroxetine label of the US Food and Drug Administration (FDA) contraindicates paroxetine with MAOIs and within 14 days of stopping them (paroxetine label, FDA). When switching from moclobemide to paroxetine, give the first paroxetine dose no earlier than 24 hours after stopping moclobemide, with caution and gradual dose increases (paroxetine SmPC, AEMPS). The FDA label requires a gap of at least 14 days after any MAOI (paroxetine label, FDA). When switching the other way, allow at least one week (paroxetine SmPC, AEMPS) or at least 14 days (paroxetine label, FDA) between the last paroxetine dose and the first moclobemide dose. Take the half-life of the previous antidepressant into account (moclobemide SmPC, AEMPS). If signs of serotonin syndrome appear, stop paroxetine and any other serotonergic drug at once and start supportive treatment (paroxetine label, FDA). Keep the patient under medical observation, in hospital if needed (moclobemide SmPC, AEMPS). Explain the risk of serotonin syndrome to the patient and ask them to tell their doctor or go to the emergency department at once if signs appear (paroxetine label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.3, 4.4 y 4.5